UroGen Pharma (URGN) announced that David Lin will join UroGen as its chief commercial officer and member of the executive leadership team. In this role, David will be spearheading UroGen’s commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of Jelmyto for pyelocalyceal solution. Lin held several key leadership positions at Bristol Myers Squibb (BMY).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: